(Q51030970)

English

A double-blind comparison of the efficacy of two dose regimens of oral granisetron in preventing acute emesis in patients receiving moderately emetogenic chemotherapy.

scientific article published in July 1996

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/8646710

A double-blind comparison of the efficacy of two dose regimens of oral granisetron in preventing acute emesis in patients receiving moderately emetogenic chemotherapy. (English)

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/8646710

1 reference

based on heuristic

inferred from title

0 references

author name string

Ettinger DS

1

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/8646710

Eisenberg PD

2

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/8646710

Fitts D

3

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/8646710

Friedman C

4

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/8646710

Wilson-Lynch K

5

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/8646710

Yocom K

6

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/8646710

language of work or name

0 references

publication date

1 July 1996

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/8646710

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/8646710

78

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/8646710

1

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/8646710

144-151

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/8646710

Incidence of nausea and vomiting with cytotoxic chemotherapy: a prospective randomised trial of antiemetics.

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819960701%2978%3A1%3C144%3A%3AAID-CNCR20%3E3.0.CO%3B2-Z

21 January 2018

On the receiving end--patient perception of the side-effects of cancer chemotherapy.

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819960701%2978%3A1%3C144%3A%3AAID-CNCR20%3E3.0.CO%3B2-Z

21 January 2018

The biological significance of soluble interleukin-2 receptors in solid tumors

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819960701%2978%3A1%3C144%3A%3AAID-CNCR20%3E3.0.CO%3B2-Z

21 January 2018

The control of acute cisplatin-induced emesis--a comparative study of granisetron and a combination regimen of high-dose metoclopramide and dexamethasone. Granisetron Study Group

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819960701%2978%3A1%3C144%3A%3AAID-CNCR20%3E3.0.CO%3B2-Z

21 January 2018

Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. A multicenter, randomized, double-blind, crossover study.

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819960701%2978%3A1%3C144%3A%3AAID-CNCR20%3E3.0.CO%3B2-Z

21 January 2018

Dose ranging phase I study of the serotonin antagonist GR38032F for prevention of cisplatin-induced nausea and vomiting

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819960701%2978%3A1%3C144%3A%3AAID-CNCR20%3E3.0.CO%3B2-Z

21 January 2018

Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis.

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819960701%2978%3A1%3C144%3A%3AAID-CNCR20%3E3.0.CO%3B2-Z

21 January 2018

Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. The Granisetron Study Group.

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819960701%2978%3A1%3C144%3A%3AAID-CNCR20%3E3.0.CO%3B2-Z

21 January 2018

Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819960701%2978%3A1%3C144%3A%3AAID-CNCR20%3E3.0.CO%3B2-Z

21 January 2018

Dose finding study of granisetron in patients receiving high-dose cisplatin chemotherapy. The Granisetron Study Group

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819960701%2978%3A1%3C144%3A%3AAID-CNCR20%3E3.0.CO%3B2-Z

21 January 2018

Inhibition of cisplatin-induced vomiting by selective 5-hydroxytryptamine M-receptor antagonism

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819960701%2978%3A1%3C144%3A%3AAID-CNCR20%3E3.0.CO%3B2-Z

21 January 2018

Selective and functional 5-hydroxytryptamine3 receptor antagonism by BRL 43694 (granisetron).

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819960701%2978%3A1%3C144%3A%3AAID-CNCR20%3E3.0.CO%3B2-Z

21 January 2018

Antiemetic activity of high doses of metoclopramide combined with methylprednisolone versus metoclopramide alone in cisplatin-treated cancer patients: a randomized double-blind trial of the Italian Oncology Group for Clinical Research.

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819960701%2978%3A1%3C144%3A%3AAID-CNCR20%3E3.0.CO%3B2-Z

21 January 2018

Protection from nausea and vomiting in cisplatin-treated patients: high-dose metoclopramide combined with methylprednisolone versus metoclopramide combined with dexamethasone and diphenhydramine: a study of the Italian Oncology Group for Clinical Re

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819960701%2978%3A1%3C144%3A%3AAID-CNCR20%3E3.0.CO%3B2-Z

21 January 2018

Modulation by 5-HT3 and 5-HT4 receptors of the release of 5-hydroxytryptamine from the guinea-pig small intestine

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819960701%2978%3A1%3C144%3A%3AAID-CNCR20%3E3.0.CO%3B2-Z

21 January 2018

Oral granisetron alone and in combination with dexamethasone: a double-blind randomized comparison against high-dose metoclopramide plus dexamethasone in prevention of cisplatin-induced emesis. The Granisetron Study Group

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819960701%2978%3A1%3C144%3A%3AAID-CNCR20%3E3.0.CO%3B2-Z

21 January 2018

5-HT3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy—A randomised study

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819960701%2978%3A1%3C144%3A%3AAID-CNCR20%3E3.0.CO%3B2-Z

21 January 2018

Serotonin antagonists: a new class of antiemetic agents

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819960701%2978%3A1%3C144%3A%3AAID-CNCR20%3E3.0.CO%3B2-Z

21 January 2018

Intravenous granisetron--establishing the optimal dose. The Granisetron Study Group

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819960701%2978%3A1%3C144%3A%3AAID-CNCR20%3E3.0.CO%3B2-Z

21 January 2018

Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819960701%2978%3A1%3C144%3A%3AAID-CNCR20%3E3.0.CO%3B2-Z

21 January 2018

Phase III double-blind comparison of intravenous ondansetron and metoclopramide as antiemetic therapy for patients receiving multiple-day cisplatin-based chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819960701%2978%3A1%3C144%3A%3AAID-CNCR20%3E3.0.CO%3B2-Z

21 January 2018

A double-blind, randomised, crossover comparison of granisetron and ondansetron in 5-day fractionated chemotherapy: assessment of efficacy, safety and patient preference. The Granisetron Study Group

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819960701%2978%3A1%3C144%3A%3AAID-CNCR20%3E3.0.CO%3B2-Z

21 January 2018

Antiemetic treatment with oral granisetron in patients receiving moderately emetogenic chemotherapy: a dose-ranging study

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819960701%2978%3A1%3C144%3A%3AAID-CNCR20%3E3.0.CO%3B2-Z

21 January 2018

Dose granisetron remain effective over multiple cycles? The Granisetron Study Group

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819960701%2978%3A1%3C144%3A%3AAID-CNCR20%3E3.0.CO%3B2-Z

21 January 2018

The Natural Course of Emesis After Carboplatin Treatment

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819960701%2978%3A1%3C144%3A%3AAID-CNCR20%3E3.0.CO%3B2-Z

21 January 2018

Efficacy and safety of antiemetics

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819960701%2978%3A1%3C144%3A%3AAID-CNCR20%3E3.0.CO%3B2-Z

21 January 2018

Identifiers

10.1002/(SICI)1097-0142(19960701)78:1<144::AID-CNCR20>3.0.CO;2-Z

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/8646710

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/8646710

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51030970&oldid=1568283132"